Palvella Therapeutics — Third Quarter 2026 Earnings Summary

The FDA has accepted Palvella Therapeutics' New Drug Application for QTORIN rapamycin to treat microcystic lymphatic malformations and granted it Priority Review, setting a target action date of February 28, 2027. If approved, QTORIN rapamycin would become the first FDA-approved therapy for this rare condition, with the company preparing for a standalone U.S. commercial launch in the first half of 2027. Palvella reported cash, cash equivalents, and short-term investments of $236.7 million as of September 30, 2026, alongside a net loss of $24.6 million for the third quarter of 2026. The company is advancing multiple additional QTORIN programs for cutaneous venous malformations, angiokeratomas, and disseminated superficial actinic porokeratosis, with plans to announce new indications and product candidates by the end of 2026.